SKIN cancer patients with an advanced form of the disease could be treated more effectively with a new drug compared to traditional chemotherapy, research has found.
A German trial tested how patients suffering from BRAF mutation-positive melanoma responded to treatment with dabrafenib.
Dabrafenib works by blocking a key signaling protein responsible for the spread of malignant melanomas. It is estimated that about half of melanomas carry the mutated form of the BRAF gene that allows the drug to work.
We moderate all comments on HeraldScotland on either a pre-moderated or post-moderated basis. If you're a relatively new user then your comments will be reviewed before publication and if we know you well then your comments will be subject to moderation only if other users or the moderators believe you've broken the rules, which are available here.
Moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours. Please be patient if your posts are not approved instantly.
